Vizgen is the life sciences company developing the next generation of Spatially Resolved Transcriptomics.

Biotechnology

Vizgen

Elizabeth has over a decade of life science commercial experience in sales and business development. She started her career at Thermo Fisher Scientific (Life Technologies/Invitrogen/Applied Biosystems) where she developed an expertise in genomics, molecular technologies and diagnostics, and then moved into the single-cell research arena.

Elizabeth received a BA in Neuroscience from Smith College and an MS in Biotechnology from Georgetown University.

Elizabeth Hicks-Kridel

Gerry Zang

Séamus has 25+ years’ experience in financial analysis in the Biotech, Medical Device and Electronic Materials industries. During his career, he has gained international experience from multi-year expatriate assignments in Asia, France, and the UK. Séamus is a fellow of the Chartered Association of Certified Accountants and has a Master of Business Studies degree from the Smurfit School of Business.

Seamus Gillespie

Marijn E. Dekkers is founder and chairman of Novalis LifeSciences LLC, an investment and advisory firm for the Life Science industry that he founded in 2017. From 2010-2016, Dr. Dekkers served as CEO of Bayer AG in Leverkusen, Germany. From 2002-2009, he was CEO of Thermo Fisher Scientific in Waltham, MA, USA. He started his career as a research scientist at General Electric’s Corporate R&D Center in Niskayuna, NY, USA.

Marijn E. Dekkers

Andrea Jackson is a Director at Northpond Ventures on the firm’s convergent technologies team. Andrea is a Board Director at several digital health and patient engagement companies, including Deep Lens, Hawthorne Effect, Octave Bioscience, Outcomes4Me, and SimBioSys. She is also a Board Director at life science software technology companies, including Saama, Scitara Corporation, Syapse, and VieCure; as well as at R&D solutions companies, including Codex DNA (NASDAQ: DNAY), Elephas Bio, Isolation Bio Inc. (formerly General Automation Lab Technologies), Refeyn, and Vizgen. Andrea also served on the board at Current Health (acquired by Best Buy) and NanoView Biosciences (acquired by Unchained Labs). Previously, Andrea was the commercial lead at Farcast Biosciences, an oncology clinical diagnostic company.

Prior to Farcast, Andrea held various senior commercial leadership roles in life science startups and large companies such as PerkinElmer (NYSE: PKI) and Millipore. Before her operating roles, Andrea worked in JPMorgan’s Healthcare Investment Banking team and focused on life science tools, diagnostics, and biotechnology companies.

Andrea received an MBA from Kellogg School of Management at Northwestern University and a B.A. with honors from Washington University in St. Louis.

Andrea Jackson

Mr. Posard brings over 30 years of general management and commercialization experience in the life sciences, therapeutics, and diagnostics industry to the Board of Directors. He is the Founding Principal of Explore DNA, a life sciences executive consulting firm, a position he has held since March 2016. Since 2017, he has provided advisory services to CEOs for several emerging life sciences companies. From February 2017 to April 2018, Mr. Posard served as President and Chief Commercial Officer of GenePeeks, Inc., a genetic research company. From March 2015 to April 2016, he served as Chief Commercial Officer of Trovagene, Inc., a molecular diagnostic biotechnology company. From February 2006 to February 2015, he held various commercial and general management positions at Illumina, Inc., a genomics company focusing on DNA sequencing, including senior executive positions overseeing Global Sales, Marketing, and General Manager of Clinical and Consumer Genomics as well as New and Emerging Markets.

Mr. Posard holds a BA degree in Management Science from the University of California, San Diego.

Matt Posard

Keith Crandell is a Managing Director and Co-Founder of ARCH Venture Partners, L.P., a global seed, and early-stage venture capital firm focused on innovations in the life and physical sciences. Keith holds an M.B.A. from The University of Chicago (Booth), an M.S. in Chemistry from the University of Texas at Arlington, and a B.S. in Chemistry and Mathematics from St. Lawrence University.

Keith L. Crandell

Dale joined Vizgen with almost 20 years’ experience in the sales and marketing of diagnostics and genomics tools, with a track record of driving dramatic commercial growth. As VP of Worldwide Sales at NanoString Inc. (NASDAQ: NSTG), he specialized in developing global sales channels and strategies from the ground up. He expertly led NanoString from less than $10MM to over $125MM in global revenue in only 5.5 years. Prior to that, Dale led commercial activities for the PCR Division at Illumina Inc. (NASDAQ: ILMN) following the company’s acquisition of Helixis, an advanced nucleic acid tools company, where he was the Senior Director for Global Sales. Most recently as VP, Worldwide Sales and Marketing at Dropworks Inc, he led all commercial activities for the company’s Serial Flow Digital Droplet platform. Dale holds a Bachelor of Science with honors degree in Molecular Biology and Genetics from La Trobe University in Melbourne, Australia

Dale Levitzke

Phil Gardella is the current Chief Financial Officer at [Vizgen](/org/vizgen). Phil has also held this position at PowerSteering Software, Inc., where they were responsible for the financial management of a web-based project portfolio management solution. Gardella has also been Chief Financial Officer & VP Finance at Vitts Networks and at Bluesocket, Inc., a venture-backed leader in open wireless security and management.

Phil Gardella has a Master of Business Administration (MBA) from the Babson F.W. Olin Graduate School of Business and a BS in Accounting from [Northeastern University](/org/northeastern-university).

Their manager is Terry Lo, President & CEO. Phil Gardella works with Elizabeth Hicks-Kridel - Director of Business Development, Dale Levitzke - SVP, Global Sales & Support, and Yoni Bock - VP, Reagents R&D.

Phil Gardella

Xiaowei Zhuang, PhD, is a co-founder and board member at [Vizgen](/org/vizgen). Xiaowei was previously a postdoctoral fellow at [Harvard University](/org/harvard), where they developed technologies for spatially-resolved, single-cell transcriptomics. Xiaowei has also worked as a research assistant at JILA, where they developed new data analysis tools for extracting relevant information from single-molecule experiments.

[
Xiaowei Zhuang, PhD, is a Biophysicist who attended [Harvard University](/org/harvard) for their Doctor of Philosophy degree. Prior to that, they completed their undergraduate studies at the [University of Colorado Boulder](/org/university-of-colorado-boulder), where they earned a Bachelor of Science in Applied Mathematics, as well as a Bachelor of Arts in Molecular Biology.

Xiaowei Zhuang, PhD

David Walt is a Co-Founder & Board Member at [Vizgen](/org/vizgen). David was previously a Hansjörg Wyss Professor of Biologically Inspired Engineering at [Harvard University](/org/harvard) from July 2017 to July 2017. Prior to that, they were at Harvard Medical School. David was also at [Tufts University](/org/tufts-university) from January 1981 to December 2017 where they were a University Professor.

David Walt, PhD received their Bachelor of Science in Chemistry from the University of Michigan and their Doctor of Philosophy in Chemical Biology from [Stony Brook University](/org/stony-brook-university).

David Walt, PhD

Jiang He, PhD, is a scientific co-founder at [Vizgen](/org/vizgen). Prior to that, they worked as a postdoctoral associate at the Massachusetts Institute of Technology (MIT) from December 2015 to October 2019. Jiang's research focuses on the interface of cell biology, biomedical-imaging and nanomedicine.

From November 2015 to August 2017, Jiang Jiang was also an author for "Walking Out A Way of My Own (Chinese Edition)".

Jiang He, PhD, earned their Doctor of Philosophy in Biochemistry, Biophysics and Molecular Biology from [Harvard University](/org/harvard). Jiang also has a Bachelor's Degree in Biology/Biological Sciences, General from the University of Science and Technology of China. In addition, they attended [Harvard Business School](/org/harvard-business-school) to learn about commercializing science.

Jiang He, PhD

George Emanuel, PhD, is the scientific co-founder of [Vizgen](/org/vizgen). Prior to that, they were a postdoctoral fellow at [Harvard University](/org/harvard), where they developed technologies for spatially-resolved, single-cell transcriptomics. George has also worked as a research assistant at JILA, where they developed new data analysis tools for extracting relevant information from single-molecule experiments. Dr. Emanuel received their PhD in physics from the [University of Colorado Boulder](/org/university-of-colorado-boulder).

George Emanuel, PhD earned their doctorate in biophysics from [Harvard University](/org/harvard). George also holds a Bachelor of Science in applied mathematics from the [University of Colorado Boulder](/org/university-of-colorado-boulder), as well as a Bachelor of Arts in molecular biology from the same institution.

George Emanuel, PhD

Heidi Creighton

Terry Lo is President and CEO of [Vizgen](/org/vizgen), a biotech startup commercializing the next generation of spatially resolved, single-cell genomics tools to power the future of research and discovery. Mr. Lo is a pioneer in the emerging Spatial Biology market and has a proven track record of driving exceptional growth across global life sciences organizations.

In addition to over two decades of experience in scaling and building global biopharma and diagnostic organizations, he is an expert in developing global business strategies for massive market growth with innovative products.

A highlight of his career was evidenced during his tenure at Roche Diagnostics, where he was instrumental in driving a paradigm shift in the standard of care benefiting millions of women worldwide through the implementation of HPV primary screening in cervical cancer screening.

He holds an MBA from the University of Chicago Booth School of Business, an MS in Microbiology from [Virginia Tech](/org/virginia-tech), and dual BS degrees in Molecular Genetics and Psychology from [The Ohio State University](/org/the-ohio-state-university).

Terry Lo

Susan Tousi is Chief Commercial Officer at Illumina, where she leads global sales, commercial operations, and commercial strategy and enablement. Susan combines her extensive general management leadership and deep technical knowledge of Illumina’s product portfolio to ensure the global commercial success of the organization. She is committed to empowering Illumina customers with innovations to further unlock the power of the genome.

Susan has been with Illumina since 2012, and previously led the product development organization as Chief Product Officer. During that time, she was responsible for global engineering, consumables, sequencing applications, IVD, software and informatics development efforts: During this time, she oversaw the most impactful decade of product launches including: HiSeq X, NovaSeq, MiSeq Dx, NextSeq 550Dx/1000/2000, iSeq, VeriSeq NIPT, TSO500, COVIDSeq, DRAGEN, and Illumina Connected Analytics. Additionally, she led the acquisition of Edico Genomics, BlueBee, and Enancio, combined with Illumina’s existing software solutions, these new capabilities enable scalable, seamless, end-to-end software solutions that drive the utilization of genomic data and accelerate the adoption of genomic data in clinical care.

Susan has more than 25 years of R&D and business leadership at Fortune 100 technology companies and within the life sciences industry. Formerly, she was Corporate Vice President and General Manager for Eastman Kodak’s Consumer Inkjet Systems organization. Prior to joining Kodak, Susan was an R&D program manager for Phogenix Imaging LLC, a joint venture start-up of Hewlett-Packard and Kodak. She previously spent 10 years with Hewlett-Packard in technical and management roles. Along with many academic honors, she has received numerous awards in both business and technology. In 2018, Susan was elected to the National Academy of Engineers. Susan was named one of the 50 Top Diverse Leaders for 2020 by the California Diversity Council and is a member of the International Women’s Forum, a global organization of preeminent women of significant and diverse achievement.

Susan holds an MBA degree from UCLA and an Honors BS in Engineering Science and Mechanics from Pennsylvania State University.

Susan serves as an executive trustee at the world renowned La Jolla Playhouse and on the UCSD Jacobs School of Engineering Dean’s Council of Advisors.

Susan Tousi

Yoni is a seasoned technology and genomics professional with 15+ years of experience successfully leading the development of next generation sequencing products and technologies (instruments, library preparation, genetic assays, and therapeutics) in the pharmaceutical, biotechnology, and life science industry. Yoni has been instrumental in launching, developing, and significantly enhancing the bottom-line profitability and quality across products and technologies in GXP, CLIA, and RUO environments for companies including Illumina and 10x Genomics. Yoni received his PhD in Organic Chemistry from The University of California, Santa Cruz.

Yoni Bock

Bob is an accomplished business leader with over three decades of experience in medical device and biotech manufacturing. He has successfully led multiple cGMP and life science instrument, reagent and consumables manufacturing and supply chain operations in a variety of business settings, from early-stage startups (CytoLogix, acquired by Dako) to multi-site leadership for Roche Diagnostics’ sequencing and target enrichment businesses, where he also served on the Global Operations Leadership Team. Bob has a BS in Electrical Engineering from Brown University and an MBA from Harvard Business School.

Bob Koshgarian

Jeffrey Moffitt, PhD

Peidong Wang is currently the VP of Engineering at [Vizgen](/org/vizgen). Peidong has over 19 years of experience in the field of spectroscopy and optoelectronics. Previously, they were the Director of Advanced Technology at [Thermo Fisher Scientific](/org/thermo-fisher-scientific), where they focused on the development of Raman, FTIR, NIR, LIBS, and XRF spectroscopy. Peidong also co-founded Ahura Scientific, where they pioneered the development of portable and handheld spectroscopy. Peidong has also held positions at Nortel Networks and Coretek.

Peidong Wang received their Ph.D. in Physics from [Imperial College London](/org/imperial-college-london).

Their manager is Terry Lo, President & CEO. They work with Dale Levitzke - SVP, Global Sales & Support, Yoni Bock - VP, Reagents R&D, and Bob Koshgarian - VP, Operations.

Teams at Vizgen

Discover similar companies